MedTrace Logo

INK Cells As Maintenance Therapy After Chemoradiotherapy for Small Cell Lung Cancer

NCT06747832 · Status: ENROLLING_BY_INVITATION · Phase: EARLY_PHASE1 · Type: INTERVENTIONAL · Enrollment: 10

Last updated 2024-12-24

No results posted yet for this study

Summary

This is a clinical study on the use of iNK cells for the treatment of small cell lung cancer.

Conditions

Interventions

DRUG

iNK cells

Intravenous infusion of iNK cells is given to the subject, 5\*108 to 1\*109 cells/dose, three doses per week, a total of 6 doses. And then 1\*109 cells/dose, one doses every 4 weeks , a total of 5 doses.

Sponsors & Collaborators

  • Weifang People's Hospital

    collaborator OTHER

  • Guangzhou Ruixin Biotechnological Co., LTD

    lead INDUSTRY

Principal Investigators

  • Yu Guohua Guohua Yu, Director of the Cancer Dpartment · Weifang People's Hospital

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-12-15
Primary Completion
2026-06-14
Completion
2026-12-14

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06747832 on ClinicalTrials.gov